Navigation Links
New therapeutic targets in the treatment of ulcerative colitis
Date:11/13/2007

Social, environmental and dietary changes are associated with the changes of disease spectrum in a country. Ulcerative colitis has become a commonly seen disease in China, probably due to extensive consumption of Western foods in recent years. Unfortunately, the etiology and pathogenesis of ulcerative colitis have not been clarified yet. Therefore, no effective etiological treatment is available at present. But a recent study published in issue 44 of the World Journal of Gastroenterology may offer new insight into this difficult-to-treat disease.

A research team from the First Affiliated Hospital of Dalian Medical University's Department of Gastroenterology, China, led by Professor Ying-De Wang, investigated the expression of matrix metalloproteinase-1 (MMP-1) and tumor necrosis factor- (TNF-alpha). MMP-1 is a peptidase that degrades the extracellular matrix in the colonic mucosa, while TNF-alpha is an important and harmful inflammatory cytokine produced in macrophages in colon. The research team found that both MMP-1 and TNF-alpha were over expressed in the colonic mucosa of patients with ulcerative colitis. The over expressed MMP-1 excessively degrades the extracellular matrix, and subsequently damages the colonic mucosa and causes ulceration and inflammatory changes in ulcerative colitis, and the over expressed TNF-alpha directly damages the colon mucosa. MP-1 and TNF-alpha proteins have the so-called synergistic action. The study revealed that the excessively expressed TNF-alpha stimulated MMPs secreting cells to produce more MMP-1, aggravating the mucosa damage. Meanwhile, MMP-1 promoted secretion of TNF-alpha in a positive feedback manner to cause further injury in the mucosa of colon. So it is very likely both MMP-1 and TNF-alpha play a central role in the development of ulcerative colitis.

Because of the important functions of MMP-1 and TNF-alpha in the development of ulcerative colitis, they have become therapeutic targeting proteins in the treatment of ulcerative colitis. It has been reported that agents of MMPs inhibitor and anti-TNF-alpha antibody were developed in Europe and America. For example, a TNF-alpha antagonist, Infliximab, has been shown to be effective against adult and child patients with ulcerative colitis. It has been approved by the FDA for clinical use in patients with Crohn's disease, another inflammatory bowel disease similar to ulcerative colitis. But MMPs inhibitor has only been used to treat experimental animal models of ulcerative colitis. The clinical application of MMPs inhibitor awaits future studies.

The results of this study will undoubtedly bring about a new round of research on the pathogenesis and new methods of treating ulcerative colitis. This will be a step toward a promising future in the battle against ulcerative colitis.


'/>"/>

Contact: You-De Chang
y.d.chang@wjgnet.com
86-108-538-1892
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... ... summer is just around the corner. Summer means a lot of different things to people. ... play all day and night. Parents often lament the coming of summer as they will ... means trips to the beach, backyard cookouts, fireworks on the Fourth of July, and even ...
(Date:5/5/2016)... ... May 05, 2016 , ... If you don’t mind a bit of ... you may want to consider a treatment that some have called the next great ... , Microneedling, also known as skin needling, is a procedure using a device ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... certifications, is pleased to announce its new referral program, giving participants incentive for ... is a tight-knit community, and we know many professionals share resources with their ...
(Date:5/5/2016)... Rolling Meadows, Ill. (PRWEB) , ... May 05, 2016 , ... ... – 5 percent more than 2014 and up 27 percent since 2012. , The ... of trends – including another annual increase in skin cancer treatments and the growing ...
(Date:5/5/2016)... ... 2016 , ... Pigment Laser Tattoo Removal Center is proud to be the ... laser, the first 4-wavelenth picosecond laser to receive FDA Clearance. This new laser ... the market. Jeremy Miller, Tattoo Artist and former reality show contestant on Spike ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... First Quarter 2016 Highlights , Generated Cash ... Flow") of $13.6 million for the first quarter of ... for the first quarter of 2016; , Paid ...
(Date:5/4/2016)... According to a new market ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... (BCI) market  is expected to reach a value of ... expand at a CAGR of 14.9 % during the ... BCI device provides collaboration between the brain and an ...
(Date:5/4/2016)... ORANGE COUNTY, Calif. , May 4, 2016  It,s time for an upgrade. ... interface shown on a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers ... top brands as well as a world class manufacturer of innovative technology.  ... ... ...
Breaking Medicine Technology: